When was BioRegen founded?

BioRegen was founded in 2008 and raised its 1st funding round 8 years after it was founded.

Where is BioRegen located?

BioRegen is headquartered in Changzhou, China.

How many employees does BioRegen have?

As of May 31, 2026, the latest employee count at BioRegen is 11.

Is BioRegen a funded company?

BioRegen is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Jun 13, 2016.

When was the latest funding round of BioRegen?

BioRegen's latest funding was a $***** Series A round on Jun 13, 2016, with participation from 0 investor.

Where does BioRegen rank among its competitors?

BioRegen ranks 29th amongst 90 active competitors, of which 25 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Cellbricks Therapeutics, which secured $8.11M in Mar, 2026.

Who are the top competitors of BioRegen?

BioRegen's top competitors include RevBio, Avisi Technologies and LambdaVision. Among them, Cellbricks Therapeutics secured the most recent funding round in March, 2026.

BioRegen - 2026 Company Profile, Funding & Competitors

Company Details

BioRegen develops biomaterials for various therapeutic indications, including otology, ob-gyn, orthopedics, etc. Its proprietary BioRegen is a 3D medical material that possesses high structural similarity with natural biological materials. The company designs the composition/structure of the material, regulate cells’ adhesion, migration, growth, differentiation, and function. The company's first product on the market is PureRegen, indicated for use as a filler after endoscopic sinus surgery, wound treatment.

Website: bioregenmed.com
Email ID: *****@bioregenmed.com

Key Metrics

Founded Year

2008

Location

Changzhou, China

Stage

Series A

Latest Funding Round

Series A, Jun 13, 2016, $*****

Investors

Eight Roads Ventures & 4 more

Ranked

29^th among 90 active competitors

Employee Count

11 as on May 31, 2026

Similar Companies

RevBio & 110 more

View BioRegen's full profile

BioRegen has raised funding over 1 round. BioRegen has 5 institutional investors.

Here is the list of recent funding rounds of BioRegen:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 13, 2016	4636658	Series A	6482235	8249000	3850451	8859190

Access funding benchmarks and valuations. Sign up today!

View details of BioRegen's funding rounds and investors

BioRegen's employee count trend

BioRegen has 11 employees as of May 26. Here is BioRegen's employee count trend over the years:

Uncover BioRegen's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of BioRegen include RevBio, Avisi Technologies and LambdaVision. Here is the list of Top 10 competitors of BioRegen, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	RevBio 2014, Lowell (United States), Series B	Developer of synthetic adhesive used for bone/dental repair	$27.5M	Pacific Dental Services, The JHA Capital & 4 others	63/100
2nd	Avisi Technologies 2017, Philadelphia (United States), Series A	Developer of nano-materials	$15.7M	MedVenture Partners, MedTech Innovator & 21 others	61/100
3rd	LambdaVision 2009, Farmington (United States), Public	Provider of a protein-based retinal prosthesis for retinal degenerative diseases	$7.65M	Seven Seven Six, Aurelia Foundry & 9 others	57/100
4th	Spiderwort 2017, Ottawa (Canada), Series A	Developer of plant-based biomaterials for repair and regeneration of tissues	$16.1M	Horizons Ventures, Flucas Ventures & 10 others	54/100
5th	CGbio 2006, Seongnam-si (South Korea), Unfunded	Solutions for the spectrum of spinal disorders, dentistry, dermal filer and wound management.	-	-	49/100
6th	ProFibrix 2004, Leiden (Netherlands), Acquired	Powdered fibrin sealant for surgical bleeding	$33M	Gilde Healthcare, Index Ventures & 3 others	47/100
7th	Dimension Inx 2017, Chicago (United States), Series A	Provider of 3D bio materials for regenerative medicine	$17.6M	Prime Movers Lab, KdT Ventures & 11 others	47/100
8th	ParaGen Technologies 2016, Columbus (United States), Series A	Developer of tissue engineering technologies	$11.6M	Ikove Capital Partners, JointJourney & 2 others	45/100
9th	HTL Biotechnology 1992, Javene (France), Acquired	Developer of biopolymers for therapy purposes	-	-	45/100
10th	Cellbricks Therapeutics 2016, Berlin (Germany), Seed	Developer of implantable tissue therapeutics using biofabrication	$8.11M	Silicon Roundabout Ventures, Brooks Hill Partners ... & 2 others	43/100
29th	BioRegen 2008, Changzhou (China), Series A	Developer of bio-materials for various therapeutic indications	-	Eight Roads Ventures, F-Prime Capital & 3 others	31/100